Feng Gang, Jiang Hongyu, Chen Ying
School of Medical Technology, Xuzhou Medical University, Xuzhou, 221004, China.
The Fourth People's Hospital of Lianyungang City, Lianyungang, Jiangsu Province, China.
BMC Infect Dis. 2025 Jan 11;25(1):55. doi: 10.1186/s12879-025-10446-z.
Tuberculosis (TB) is a global problem that seriously jeopardizes human health. Among them, the diagnosis and treatment of smear- or culture-negative TB patients is a challenge. The Xpert MTB/RIF (Xpert) assay has been reported to be a novel molecular diagnostic tool for rapidly detecting TB. Still, there is limited data on this assay's performance in subgroups of TB patients. This study aimed to evaluate the diagnostic value of the Xpert method in patients with different smear and culture results and to assess its efficacy for rifampicin resistance (RR) detection.
We retrospectively collected data from 1,721 patients with a clinical diagnosis of tuberculosis. Smear, Xpert, and traditional solid culture methods were used to detect TB infection and explore the detection rate of Xpert in the grouping of results from different smear and culture methods. Information on RR detected by the Xpert method and proportional method of drug sensitivity test (DST) was also recorded and kappa values, sensitivity, and specificity were calculated.
We observed that among the three methods, the Xpert method had the highest detection rate of 66.8%, followed by the culture method at 56.0% and the smear method had the lowest at 40.0%. The detection rate of Xpert was 98.3% (642/653) when both smear and culture were positive, 85.1% (296/348) when only one of the two methods, smear and culture, was positive, and 29.4% (212/720) when both smear and culture were negative. The Xpert method and DST showed a high agreement (κ = 0.92) for RR detection. The highest mutation rate was observed for probe E (64.7%), and the least number of probe C mutations occurred (1.5%).
The Xpert method has high detection efficiency. It has good diagnostic value in detecting MTB and RR, especially in cases where traditional culture and sputum smear results are negative, and significantly reduces the rate of missed diagnosis.
结核病是一个严重危害人类健康的全球性问题。其中,涂片或培养阴性结核病患者的诊断和治疗是一项挑战。Xpert MTB/RIF(Xpert)检测已被报道为一种快速检测结核病的新型分子诊断工具。然而,关于该检测在结核病患者亚组中的性能数据有限。本研究旨在评估Xpert方法在不同涂片和培养结果患者中的诊断价值,并评估其对利福平耐药性(RR)检测的效能。
我们回顾性收集了1721例临床诊断为结核病患者的数据。采用涂片、Xpert和传统固体培养方法检测结核感染,并探讨Xpert在不同涂片和培养方法结果分组中的检出率。还记录了Xpert方法检测的RR信息以及药物敏感性试验(DST)的比例法,并计算kappa值、敏感性和特异性。
我们观察到,在这三种方法中,Xpert方法的检出率最高,为66.8%,其次是培养方法,为56.0%,涂片方法最低,为40.0%。当涂片和培养均为阳性时,Xpert的检出率为98.3%(642/653);当涂片和培养两者中只有一项为阳性时,检出率为85.1%(296/348);当涂片和培养均为阴性时,检出率为29.4%(212/720)。Xpert方法和DST在RR检测方面显示出高度一致性(κ = 0.92)。观察到探针E的突变率最高(64.7%),探针C的突变数最少(1.5%)。
Xpert方法具有较高的检测效率。它在检测结核分枝杆菌和RR方面具有良好的诊断价值,尤其是在传统培养和痰涂片结果为阴性的情况下,显著降低了漏诊率。